IMIDomics

IMIDomics, founded in 2015, is a biotechnology company focused on the discovery and development of new drugs for the treatment of immune-mediated inflammatory diseases (IMID). The company's Precision Discovery Platform integrates and analyzes clinical, epidemiological, and biomolecular data to uncover novel insights into IMIDs, including lupus, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. As an innovative leader in the discovery and application of biomarkers and novel targets for monitoring and treating IMIDs, we create value by combining the world’s largest IMID biobank, extensive related clinical expertise, high-throughput genomic and genetic analyses, and intellectual property.